Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981540 | 0.95 | CYP1A2 (0.42) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL596794 | 0.94 | MAPT (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL26978299 | 0.94 | MAPT (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL138410 | 0.90 | PSMB8 (0.31) | PSMB8PSMB5 | |
| SCHEMBL12101932 | 0.90 | CYP1A2 (0.31) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL6572156 | 0.85 | KMT2A (0.32) | KMT2ASMN1; SMN2PSMB8PSMB5 | |
| SCHEMBL290461 | 0.84 | SMN1; SMN2 (0.40) | KMT2ASMN1; SMN2PSMB8PSMB5 | |
| SCHEMBL22777675 | 0.84 | SMN1; SMN2 (0.36) | KMT2ASMN1; SMN2PSMB8PSMB5 | |
| SCHEMBL34383 | 0.84 | SMN1; SMN2 (0.36) | KMT2ASMN1; SMN2PSMB8PSMB5 | |
| SCHEMBL905722 | 0.82 | SMN1; SMN2 (0.42) | KMT2ASMN1; SMN2PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109631-A1 | SYNTHETIC DELIVERY SYSTEMS AND CONJUGATES THEREOF | MICRO CRISPR PVT. LTD. (IN) | 2025-05-30 | — | — | WO | claimed |
| WO-2025109631-A1 | SYNTHETIC DELIVERY SYSTEMS AND CONJUGATES THEREOF | MICRO CRISPR PVT. LTD. (IN) | 2025-05-30 | — | — | WO | disclosed |
| CN-119326907-A | Coupling medicine and preparation method and application thereof | 岩唐生物科技(杭州)有限责任公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-2964658-B1 | POSITRON-EMITTING SUBSTITUTED ORGANOFLUOROBORATES AS IMAGING AGENTS | UNIV BRITISH COLUMBIA (CA) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024086633-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| CN-116622468-A | Antifouling micro-bubble for biological orthogonal capture and preparation and application thereof | 广西医科大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-2591795-A1 | RNA targeting compounds and methods for making and using same | The Research Foundation Of State University Of New York (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2129388-B1 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | UNIV NEW YORK STATE RES FOUND | 2012-09-12 | — | — | EP | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20080227213-A1 | Comprising polymer backbone and two or more pendant RNA binding ligands; myotonic dystrophy | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2008-09-18 | — | — | US | disclosed |
| US-20080227213-A1 | Comprising polymer backbone and two or more pendant RNA binding ligands; myotonic dystrophy | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2008-09-18 | — | — | US | disclosed |
| WO-2008103489-A2 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080188377-A1 | Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs | USA AS REPRESENTED BY THE ADMINISTRATOR OF THE NASA | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | CYP1A2 1440/4885CYP2D6 1671/4885MAPT 2425/4885 |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | CYP1A2 4864/4885CYP2D6 4680/4885MAPT 3903/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CYP1A2 4692/4885CYP2D6 1430/4885MAPT 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.